{"blog": [], "keywords": [{"value": "Allergan Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Pfizer Inc", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Corporate Taxes", "name": "subject", "rank": "3", "is_major": "Y"}, {"value": "Taxation", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Mergers, Acquisitions and Divestitures", "name": "subject", "rank": "5", "is_major": "N"}, {"value": "Treasury Department", "name": "organizations", "rank": "6", "is_major": "N"}, {"value": "Tax Shelters", "name": "subject", "rank": "7", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/03/13/your-money/pfizers-eager-to-go-but-the-market-has-doubts.html", "document_type": "article", "byline": {"person": [{"lastname": "SOMMER", "firstname": "Jeff", "role": "reported", "organization": "", "rank": 1}], "original": "By JEFF SOMMER"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/03/13/business/13STRA/13STRA-thumbWide.jpg", "legacy": {"wide": "images/2016/03/13/business/13STRA/13STRA-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/03/13/business/13STRA/13STRA-articleLarge.jpg", "legacy": {"xlarge": "images/2016/03/13/business/13STRA/13STRA-articleLarge.jpg", "xlargeheight": "375", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 375}, {"url": "images/2016/03/13/business/13STRA/13STRA-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/03/13/business/13STRA/13STRA-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Your Money", "word_count": "1217", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "A spread in share prices suggests that the drug maker\u2019s tax inversion deal with Allergan may not yet be in the bag.", "pub_date": "2016-03-13T00:00:00Z", "news_desk": "SundayBusiness", "headline": {"kicker": "Strategies", "print_headline": "Pfizer\u2019s Eager to Go, but the Market Has Doubts", "main": "Pfizer\u2019s Eager to Go, but the Market Has Doubts", "content_kicker": "Strategies"}, "print_page": "7", "snippet": "A spread in share prices suggests that the drug maker\u2019s tax inversion deal with Allergan may not yet be in the bag.", "_id": "56e4634038f0d83a21f5bde6", "slideshow_credits": null, "abstract": "Jeff Sommer Strategies column asserts investors believe government will obstruct tax inversion merger of Allergan and Pfizer; public and politicians have been calling for end to such mergers. "}